Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
About us
Contact
Links
About us
Contact
Links
Accordion Title
Accordion Content
more items +
The bond market is signaling two things about Trump’s second term
Buffett’s Berkshire Hathaway buys more Sirius XM stock as it continues to bounce
Americans will bet a record $1.39 billion on Super Bowl LIX
Wells Fargo clears another postscandal regulatory hurdle — but more remain
AMD earnings are on deck, and investors need reassurance about AI
Investors shake off trade-war fears, but wonder how long the calm will last
Top Trump adviser says new tariffs will pay for eliminating taxes on tips
Trump, tariffs and your 401(k) — why it’s time to diversify
Should Comcast split into three? This analyst says a breakup would mean big upside.
Job openings fall close to 4-year low. Finding work gets harder.
10 growth stocks in the S&P 500’s bargain sector
Cyber cop specialist SailPoint eyes $1 billion in proceeds in IPO return
The bond market is signaling two things about Trump’s second term
Buffett’s Berkshire Hathaway buys more Sirius XM stock as it continues to bounce
Americans will bet a record $1.39 billion on Super Bowl LIX
Wells Fargo clears another postscandal regulatory hurdle — but more remain
AMD earnings are on deck, and investors need reassurance about AI
Investors shake off trade-war fears, but wonder how long the calm will last
Top Trump adviser says new tariffs will pay for eliminating taxes on tips
Trump, tariffs and your 401(k) — why it’s time to diversify
Should Comcast split into three? This analyst says a breakup would mean big upside.
Job openings fall close to 4-year low. Finding work gets harder.
10 growth stocks in the S&P 500’s bargain sector
Cyber cop specialist SailPoint eyes $1 billion in proceeds in IPO return
Regeneron’s earnings boosted by demand for blockbuster eye drug Eylea
4-02-25
A higher-dose formulation of Eylea saw U.S. sales more than double
Share this on:
